Patients must have measureable hepatic disease and/or presence of vascular tumor thrombosis (involving portal vein, IVC and/or hepatic vein) which may not be measureable as per Response Evaluation Criteria in Solid Tumors (RECIST) on liver CT or MRI, within days PRIOR TO STUDY ENTRY Subject has progressive disease with at least one measureable lesion on MRI. Histologic or cytological confirmation of a malignancy that is advanced (metastatic and/or unresectable) with measureable disease per RECIST v. Measureable disease as defined by the RECIST .. Measureable disease (defined as at least . cm in diameter). Measureable disease per response evaluation criteria (RECIST) v. For Part G, H, and I: Have measureable disease as defined by RECIST .. Patients enrolled in the expansion cohort must have at least one measureable lesion as defined by the RECIST . criteria Has measureable disease by RECIST . criteria as assessed by the local site investigator/radiology. Measureable or evaluable disease by RECIST v. for solid tumors prior to the administration of study drug Must have measureable disease as per RECIST Version . or RANO (for GBM). Measureable disease according to RECIST Version . At least one measureable lesion as defined by RECIST version . that has not been previously irradiated Measureable disease Have measureable disease At least one measureable tumor lesion that that has not been previously locally Part only: have measureable disease by RECIST Measureable disease. Measurable and/or non-measureable disease by RECIST criteria must be present Patients with measureable or non-measureable disease are eligible Measureable disease according to RECIST Version . Radiographically measureable disease. Has measureable disease Has measureable or nonmeasurable disease as defined by RECIST . criteria. Subjects must have measureable disease according to RECIST (version .). Radiographically measureable disease Radiographically measureable disease Radiographically measureable disease Measureable (target) disease. At least one measureable lesion by RECIST .. Have measureable disease per RECIST .. Subjects must have measureable disease as defined by RECIST . criteria or modified RECIST criteria Subjects who have brain metastasis as the only measureable lesion At least one measureable lesion as defined by RECIST version . that has not been previously irradiated. At least one measureable lesion. Measureable disease Measureable disease Chemoembolization is allowed if >= weeks from study entry; there are possible scenarios:\r\n* If patient has hepatic disease only: they need to have progressed in the liver since chemoembolization and have measureable disease by RECIST . in order to be eligible\r\n* If patient has hepatic and extrahepatic disease: they will need to have progressed inside OR outside the liver and have measureable disease by RECIST . in order to be eligible Measureable disease according to RECIST Version . Presence of measureable disease based on RECIST v. Subjects must have at least lesion that is measureable using RECIST guidelines Measureable disease per RECIST v. prior to administration of study medication Patients must have measureable or evaluable disease Objective, measureable, symptomatic organ involvement, defined as one or more of the following: Measureable disease as per RECIST Presence of at least one measureable tumor lesion is required Women with >= cm clinically or radiologically measureable breast cancer Previously untreated participants must have a measureable lesion on an imaging study Subject must have measureable disease by RECIST .. Presence of measureable disease based on RECIST v.. Measureable disease Presence of measureable disease based on RECIST v.